Provided by Tiger Fintech (Singapore) Pte. Ltd.

Madrigal Pharmaceuticals

348.35
+25.337.84%
Post-market: 348.350.00000.00%19:49 EDT
Volume:382.11K
Turnover:130.08M
Market Cap:7.69B
PE:-15.91
High:348.35
Open:328.50
Low:326.70
Close:323.02
Loading ...

Company Profile

Company Name:
Madrigal Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
528
Office Location:
Four Tower Bridge,Suite 200,200 Barr Harbor Drive,West Conshohocken,Pennsylvania,United States
Zip Code:
19428
Fax:
- -
Introduction:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

Directors

Name
Position
Paul A. Friedman
Chairman of the Board, Chief Executive Officer
Fred B. Craves
Lead Director
Rebecca Taub
President, Research,Development, Chief Medical Officer and Director
David Milligan
Director
James M. Daly
Director
Keith R. Gollust
Director
Kenneth M. Bate
Director
Richard S. Levy
Director

Shareholders

Name
Position
Paul A. Friedman
Chairman of the Board, Chief Executive Officer
Brian J. Lynch
Senior Vice President and General Counsel
Marc Schneebaum
Senior Vice President, Chief Financial Officer
Remy Sukhija
Senior Vice President, Chief Commercial Officer
Rebecca Taub
President, Research,Development, Chief Medical Officer and Director